METHODS
We retrospectively reviewed the medical records of pediatric patients treated at the Dana-Farber/Boston Children’s (DF/BC) Cancer and Blood Disorders Center with the VDC-ICE treatment plan and diagnosed from January 2006 to December 2016. Patients were identified through a search of the Pediatric Patient Informatics Platform and electronic chemotherapy order entry reports detailing treatment plans. These reports were reviewed for their accuracy. Patients were excluded if – despite receiving a recommendation for this treatment plan or beginning this treatment plan at DF/BC – they completed the bulk of the treatment at another institution or had shared cared with another institution, as all details on toxicity were not available. General characteristics of these patients were captured as available but were not included in the analysis. Data collected on the population of interest included patient demographics, treatment plan, and clinical course, as well as complications, toxicities, and outcomes. This study was approved by the Dana-Farber Cancer Institute Institutional Review Board.